Increased rate of pancreatitis in gender diverse and transgender patients on hormone therapy: a case series study.

Pancreatitis occurred in 7 of 1333 patients on gender-affirming hormone therapy and in 0 of 615 patients with no history of GAHT use.

• 7 patients on GAHT developed pancreatitis out of 1333 total GAHT-exposed patients
• 0 patients without GAHT history developed pancreatitis out of 615 total unexposed patients
• This represents a relative risk of 6.96 (95% CI 2.76 to 848.78) for development of pancreatitis in patients with exposure to GAHT
• Study design was a retrospective case series analysis

There is limited data on the incidence of gastrointestinal-specific pathology in gender non-conforming populations prior to this study.

• The study population included gender non-conforming (GNC) and transgender individuals
• The study specifically examined patients exposed and not exposed to gender-affirming hormone therapy (GAHT)
• The authors note clinicians working with GNC individuals should be aware of this possible association between GAHT and pancreatitis